DIAGNOS Announces Annual General Meeting of Shareholders Date and Attendance Special Measures
August 26 2020 - 1:23PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces that the 2020 annual and special
meeting of shareholders (the “Meeting”) will be held on September
28th, 2020, at 10:00 a.m., at (i) the Corporation’s new head office
located at 7005 Taschereau Blvd., Suite 265, Brossard, Quebec and
(ii) by virtual means.
Purposes of the Meeting
- To receive the annual report of
management, the audited consolidated financial statements of the
Corporation for the financial year ended March 31, 2020 and the
independent auditor’s report thereon;
- To elect the directors of the
Corporation;
- To reappoint Raymond Chabot Grant
Thornton, LLP, as independent auditor of the Corporation for the
ensuing year and to authorize the directors to fix its
remuneration;
- To approve by ordinary resolution
the amendment to the Corporation’s existing stock option plan to
increase the maximum number of common shares that may be issued
pursuant thereto, from 6,000,000 to 9,000,000, as approved by the
Board of directors on August 26th, 2020; and
- To transact such other business as
may properly come before the Meeting or any adjournment
thereof.
Attendance / participation at the
MeetingDue to COVID-19 sanitary measures, the Corporation
is strongly recommending all shareholders to vote by proxy in
advance of the Meeting. Only Registered Shareholders (as defined in
the Management Information Circular available on www.sedar.com) and
duly appointed proxyholders who intend to vote at the Meeting will
be able to attend the Meeting in person. Registered Shareholders
and Non-registered Holders (as defined in the Management
Information Circular available on www.sedar.com) who do not intend
to vote at the Meeting are kindly asked to participate via
videoconferencing. In all cases, attendees are required to contact
us by email at agm2020@diagnos.ca, or by phone at (450) 678-8882
ext. 236, to secure their attendance in person or
their remote participation. Remote participants will not be
able to vote at the Meeting. Operating costs
reductionLast April, the Corporation had undertaken a
cost-reduction exercise to reduce its fixed operating costs through
layoffs and the negotiation of a new lease for its head office.
Taking into account government aid programs related to COVID-19,
the Corporation's disbursements has been reduced by nearly 50% from
the pre-pandemic level.
Stock options grantThe Board
has approved a grant totalling 600,000 stock options to one officer
of the Corporation. Stock options vest at 50% per year, commencing
with the first anniversary of the grant. The exercise price of
these options has been established at $0.18 per share. The expiry
date to which these options can be exercised has been fixed to
August 26, 2025.
Resignation of one director The
Corporation is also announcing that, on August 25, 2020, Mr.
François Côté resigned from his position as director and chairman
of the board of directors. The board wishes to thank Mr. Côté for
his contribution to the development of DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024